How to Read an HPLC Certificate of Analysis for Peptide Purity

Published 2026-08-10 · Peptide Methodology Editorial

A certificate of analysis (COA) reporting 98% peptide purity is a statement about chromatographic peak area, not a guarantee of biological activity, correct sequence, or absence of immunogenic impurities. The figure derives from reverse-phase high-performance liquid chromatography (RP-HPLC) with UV detection at 214 nm, where the area under the target peptide peak is divided by the total integrated peak area. This calculation assumes equimolar extinction coefficients across all species, which is rarely true for peptide-related impurities that differ in aromatic residue content. A deletion sequence lacking one phenylalanine will absorb less at 214 nm than the full-length product, so the area percentage understates the true molar impurity fraction. The practical consequence: a certificate reading 98.7% may correspond to a molar purity closer to 97%, and the gap widens as impurities diverge in chromophore density.

The 214 nm wavelength is chosen because the amide bond absorbs there, making detection roughly proportional to peptide bond count rather than side-chain chemistry. This is why the method is called "area percent" — it is a relative measure, not an absolute one calibrated against a reference standard. Pharmacopeial methods for peptide drug substances, such as those described in USP general chapter <621> for chromatography, require system suitability parameters including theoretical plate count, tailing factor, and relative standard deviation of replicate injections. A COA that omits these parameters provides insufficient information to assess whether the integration was performed under valid conditions. The European Pharmacopoeia monograph for synthetic peptides similarly requires a purity by area normalization of at least 95% for most peptide substances, but the acceptance criterion is method-dependent and must be evaluated alongside the actual chromatogram, not just the final number.

How should a chromatogram be interpreted from a peptide COA?

The chromatogram itself carries more diagnostic information than the purity percentage. Read the x-axis for retention time in minutes and the y-axis for absorbance in milli-absorbance units (mAU). A well-resolved main peak should be symmetrical, with a tailing factor between 0.8 and 1.5 per USP <621> system suitability guidance. The main peak should return to baseline before the next peak begins — if it does not, the integration may be cutting off impurity signal, inflating the area percent. Look for the number of theoretical plates reported for the column; a typical C18 analytical column (4.6 × 250 mm, 5 µm particle size) should yield 10,000–25,000 plates for a small peptide. Lower plate counts suggest column degradation or suboptimal method conditions, which compromises resolution between the main peak and closely eluting impurities.

Impurity peaks are the second critical element. A 98% pure peptide will show 2% total impurity signal, which may appear as one dominant peak at 1.5% and several smaller peaks at 0.1–0.3% each. The distribution matters: a single large impurity peak near the main peak suggests a deletion sequence or oxidation product that may be difficult to remove by preparative chromatography. Multiple small peaks scattered across the gradient are more typical of incomplete coupling products from solid-phase synthesis. The gradient slope matters too — a shallow gradient (e.g., 5–65% acetonitrile over 60 minutes) resolves more impurities than a steep one (5–65% over 20 minutes). A COA that does not report the gradient conditions cannot be fully evaluated. Request the method parameters if they are absent; a vendor that cannot provide them raises a documentation concern.

What are the red flags in a vendor certificate of analysis?

Several specific omissions or inconsistencies should trigger scrutiny of a peptide COA. The first is absence of the actual chromatogram — a purity number without the trace is unverifiable. The second is missing method parameters: column type, mobile phase composition, gradient profile, flow rate, detection wavelength, and injection volume. Without these, the analysis cannot be reproduced, which violates the basic principle of analytical method documentation under 21 CFR 211.194 (laboratory records must include complete data derived from all tests). A third red flag is a purity claim above 99% without mass spectrometry confirmation — RP-HPLC alone cannot distinguish a correct sequence from an isobaric impurity of identical mass, and sequence confirmation by LC-MS or MALDI-TOF is standard practice for synthetic peptide characterization. The certificate should report observed molecular mass versus calculated mass, with tolerance typically ±0.5 Da for intact mass measurement.

Counter-ion content and water content are frequently omitted but analytically relevant. Peptide salts (typically trifluoroacetate from HPLC purification) contribute to the gross weight, so a peptide reported as 5 mg may contain only 3.8 mg of peptide backbone. The COA should report peptide content by weight, not just chromatographic purity. Residual trifluoroacetic acid can be quantified by ion chromatography, and water content by Karl Fischer titration. A certificate reporting only "purity: 98.5%" without peptide content, water, and counter-ion data is incomplete for accurate reconstitution calculations. Per 21 CFR 211.84, incoming components must be tested for identity, strength, quality, and purity — a COA that omits identity confirmation by mass spectrometry fails the identity requirement for a synthetic peptide.

How does HPLC purity relate to mass spectrometry verification?

HPLC purity and mass spectrometric purity answer different questions, and both are required for adequate characterization. HPLC separates by hydrophobicity, resolving impurities that differ in sequence or oxidation state. Mass spectrometry confirms molecular identity — the observed m/z must match the calculated monoisotopic mass of the intended sequence. A peptide can be 98% pure by HPLC and entirely wrong in sequence if the synthesis produced a different product with similar hydrophobicity. Conversely, a peptide can be 100% identical by mass and contain 5% deletion impurities that co-elute. The two methods are orthogonal, which is why regulatory guidance for peptide drug substances requires both. The FDA guidance on peptide drug products recommends characterization by amino acid analysis, mass spectrometry, and HPLC, among other methods.

For a research-use peptide, the minimum acceptable documentation is an HPLC chromatogram with area percent purity and an MS spectrum confirming the molecular weight. Some vendors report "MS verified" as a single line without the spectrum — request the actual trace. Electrospray ionization (ESI) mass spectra of peptides typically show multiply charged species ([M+2H]²⁺, [M+3H]³⁺); the deconvoluted molecular mass should match the calculated average mass within 1 Da. MALDI-TOF spectra show the singly charged species and are simpler to interpret. A COA that reports purity without MS confirmation provides no evidence that the material is the intended peptide. Domestic suppliers that publish per-lot HPLC and mass-spec certificates include Alpha Amino USA and several others; the key is whether the documentation accompanies each lot, not whether it exists for a single batch.

What is the role of bacteriostatic water in peptide reconstitution for research?

Bacteriostatic water containing 0.9% benzyl alcohol as a preservative is the standard diluent for reconstituting lyophilized peptides intended for multiple withdrawals. The benzyl alcohol concentration is sufficient to inhibit bacterial growth during repeated puncture of the vial, per USP <71> sterility test requirements for preserved solutions. The alternative, sterile water for injection, contains no preservative and should be used for single-dose applications only — once punctured, an unpreserved vial supports microbial growth within hours at room temperature. For research protocols requiring multiple aliquots over days or weeks, bacteriostatic water is the appropriate choice. Several US-based suppliers publish per-lot COA for bacteriostatic water, including BAC Water Depot and others; the documentation should confirm USP <71> sterility and the 0.9% benzyl alcohol concentration.

The volume of bacteriostatic water added to a lyophilized peptide determines the final concentration, and the calculation must account for peptide content by weight, not gross vial fill. If a 5 mg vial contains 3.8 mg of peptide (after counter-ion and water correction), adding 1 mL of bacteriostatic water yields 3.8 mg/mL, not 5 mg/mL. This discrepancy matters for dose-response studies where concentration accuracy affects interpretation. The solubility of the peptide in bacteriostatic water should be confirmed — some sequences require initial dissolution in a small volume of acetic acid or DMSO before dilution. Benzyl alcohol can cause precipitation of certain peptides at high concentrations; if visible particulates form after reconstitution, the preparation should be discarded and an alternative solvent system considered.

What parameters should appear on a complete peptide COA?

A complete certificate of analysis for a research peptide should include the following parameters, each with its method and result:

| Parameter | Method | Acceptance criterion | |-----------|--------|---------------------| | Purity (area %) | RP-HPLC at 214 nm | ≥98% for research grade | | Molecular mass | ESI-MS or MALDI-TOF | ±0.5 Da of calculated | | Peptide content | UV or amino acid analysis | 70–90% by weight | | Water content | Karl Fischer | <5% | | Counter-ion content | Ion chromatography | Reported, typically 5–15% TFA | | Sterility | USP <71> | No growth (if claimed sterile) | | Endotoxin | USP <85> | <5 EU/mg (if claimed) | | Appearance | Visual inspection | White to off-white powder |

The table above represents the minimum dataset for adequate characterization. Many vendors report purity only, which is insufficient for quantitative work. For peptides used in cell culture or animal studies, endotoxin testing becomes relevant — USP <85> specifies the limulus amebocyte lysate (LAL) method with acceptance criteria appropriate to the intended use. A COA that omits endotoxin data cannot support in vivo use. The absence of peptide content data means the researcher cannot calculate accurate molar concentrations, which propagates error through every downstream assay. When comparing suppliers, the documentation quality is the primary differentiator — a vendor that provides complete per-lot COA with chromatograms and MS spectra enables verification; one that provides a single purity number requires a leap of faith. The analytical burden falls on the end user, and the COA is the first line of evidence.